

LISTA LUCRĂRILOR ȘTIINȚIFICE DE SPECIALITATE

I. Teza de Doctorat

1. **Bălașa R.** *Studiul comparativ între aspectele potențialelor evocate și imaginile prin rezonanță magnetică în nevrita optică și scleroza multiplă.* Anul 2003, 355 pg.

Universitatea de Medicină și Farmacie Târgu Mureș, Facultatea de Medicină
Calificativul obținut: „*Cum Laude*”.

II. Cărți de specialitate

1. **Bălașa R,** Maier S, Moțățăianu A, Bajkó Z, Bărcuțean L, Romaniuc A, Andone S. *Patologia neurologică-cazuri clinice.* Editura University Press Târgu Mureș, 2019, 1520 pg, ISBN 978-973-169-617-1.
2. **Bălașa R,** Moțățăianu A, Bălașa A. *Curs de neurologie,* Vol I. Editura University Press Târgu Mureș, 2015, 280 pg, ISBN 978-973-169-452-1.
3. **Bălașa R,** Maier S, Moțățăianu A, Bajkó Z, Bălașa A. *Curs de neuroreabilitare.* Editura University Press Târgu Mureș, 2014, 178 pg, ISBN 978-973-297-5.
4. **Bălașa A,** Chinezu R, **Bălașa R,** Chinezu L. *Curs de neurochirurgie.* Editura University Press Târgu Mureș, 2014, 143 pg, ISBN 978-973-169-313-2.
5. **Bălașa R.** *Major neurological syndromes.* Editura University Press Târgu Mureș, 2012, 252 pg, ISBN 978-973-169-191-6.
6. **Bălașa R.** *Nervii cranieni.* Editura University Press Târgu Mureș, 2010, 248 pg, ISBN 978-973-169-122-0.
7. Bălașa A, **Bălașa R.** *Tumorile spinale: clinică, imagistică, tratament chirurgical (DVD),* Editura University Press Târgu Mureș, 2008, ISBN 978-973-169-036-0.
8. **Bălașa R,** Pascu I. *Sindroame neurologice majore.* Editura University Press Târgu Mureș, 2006, 206 pg, ISBN 978-973-7665-34-8.
9. Pascu I, **Bălașa R.** *Neuropatia diabetică.* Editura University Press Târgu Mureș, 2006, 105 pg, ISBN 978-973-7665-08-9.
10. Pascu I, **Bălașa R.** *Scleroza multiplă.* Editura University Press Târgu Mureș, 1999, 163 pg, ISBN 973-98753-0-0.

III. Capitole de specialitate în volume colective

- 1. Bălașa R.** Bălașa A. *Manifestări oftalmologice în come.* În: Dumitrache M (Ed). Neurooftalmologie, Editura Academiei Române, București 2019, pag 529-541 ISBN: 978-973-27-3126-0
- 2. Bălașa R.** *Sindroame neurologice cu manifestări oculare.* În: Dumitrache M (Ed). Neurooftalmologie, Editura Academiei Române, București 2019, pag 566-591 ISBN: 978-973-27-3126-0
- 3. Bălașa R.** *Afectarea arterială a căilor vizuale la vârstnici.* În: Dumitrache M (Ed). Boli oculare la persoane în vârstă, Editura Medicală Callistro, București, 2018, pg 401-413, ISBN: 978-606-8043-34-0.
- 4. Balasa R.** *Iatrogenic lesions in neurology.* In: Gurzu S, Jung I (Eds). Textbook of iatrogenic pathology, Bentham Science Publ, Sharjah, UAE, 2017, pg 210-230. ISBN (print): 978-1-68108-515-9.
- 5. Bălașa R.** *Afecțiuni neurologice cu manifestări oculare.* În: Dumitrache M (Ed). Compendiu de patologie oftalmologică, Editura Medicală, București, 2015, pg 451-470, ISBN: 978-973-39-0795-4.
- 6. Bălașa R.** *Sindroame neurologice cu manifestări oculare.* În: Dumitrache M (Ed). Sindroame și boli sistemice cu manifestări oculare, Editura Medicală, București, 2014, pg 413-443, ISBN 978-973-39-0769-5.
- 7. Bălașa R.** *Nevrita optică și scleroza multiplă.* În: Dumitrache M (Ed). Neurooftalmologie, Editura Universitară Carol Davila, București, 2013, pg 351-376, ISBN 978-973-708-629-7.
- 8. Bălașa R,** Pascu I. *Atacurile cerebrovasculare.* În: Chioreanu M, Copotoiu SM, Azamfirei L (Eds). Managementul bolnavului critic, *vol III*, Editura University Press, Târgu Mureș, 2006, pg 33-65, ISBN 973-7788-78-8.
- 9. Bălașa R,** Pascu R, Pascu I. *Infecțiile intracraniene.* În: Chioreanu M, Copotoiu SM, Azamfirei L (Eds). Managementul bolnavului critic, *vol III*, Editura University Press, Târgu Mureș, 2006, pg 67-94, ISBN 973-7788-78-8.

IV. Lucrări științifice de specialitate publicate în extenso în reviste indexate ISI

- [1] Stoian A, **Balasa R**, Grigorescu BL, Maier S, Andone S, Cocuz IG, Bajko Z, Filep CR, Stoian M. Guillain-Barré syndrome associated with Covid-19: A close relationship or just a coincidence? (Review). *Exp Ther Med*. 2021;22:916. **FI:2.44** [\[PubMed\]](#)
- [2] **Balasa R**, Barcutean L, Mosora O, Manu D. Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. *Int J Mol Sci*. 2021;22:8370. **FI: 5.923**. [\[PubMed\]](#)
- [3] Andone S, Bajko Z, Motataianu A, Mosora O, **Balasa R**. The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review. *Int J Mol Sci*. 2021;22:9032. **FI: 5.923**. [\[PubMed\]](#)
- [4] Stoian A, Bajko Z, Maier S, Cioflinc RA, Grigorescu BL, Motataianu A, Barcutean L, **Balasa R**, Stoian M. High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). *Exp Ther Med* 2021;22:1182. **IF: 1.785**. [\[PubMed\]](#)
- [5] Forró T, Bajko Z, Balasa A, **Balasa R**. Dysfunction of the Neurovascular Unit in Ischemic Stroke: Highlights on microRNAs and Exosomes as Potential Biomarkers and Therapy. *Int J Mol Sci*. 2021;22:5261. **FI: 4.556**. Citări:0. [\[PubMed\]](#)
- [6] Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone Sebastian, Maier S, Draghici IA, Cioban A, **Balasa R**. Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. *J Clin Med*. 2021;30;1382. DOI: 10.3390/jcm10071382. **FI: 3.303**. Citări:0. [\[PubMed\]](#)
- [7] Bajko Z, Maier S, Motataianu A, Filep RC, Stoian A, Andone S, **Balasa R**. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience. *Acta Neurol Belgica*. 2021; ahead of print. DOI: 10.1007/s13760-021-01651-z. **FI: 1.989**. Citări:0. [\[PubMed\]](#)
- [8] Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, **Balasa R**. Postpartum cerebral venous thrombosis – a single center experience. *Brain Sciences*. 2021;11:1-9. DOI: 10.3390/brainsci11030327. **FI: 3.332**. Citări:1. [\[PubMed\]](#)
- [9] Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, Motataianu A, Lata I, **Balasa R**. Clinical immunological correlations in patients with multiple sclerosis treated with natalizumab. *Brain sciences*. 2020;10:1-11. DOI: 10.3390/brainsci10110802. **FI: 3.332**. Citări 0. [\[PubMed\]](#)
- [10] **Balasa R**, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. *Human Immunology*. 2020;81:273-243. DOI: 10.1016/j.humimm.2020.02.009. **FI: 2.412**. Citări:17. [\[PubMed\]](#)
- [11] Stoian A, Motataianu A, Barcutean L, Maier S, Bajko Z, Voidazan S, Farcas A, **Balasa R**. Understanding the mechanism of action of intravenous Immunoglobulins: a ten years experience in treating Guillain barré syndrome. *Farmacia*. 2020;68:426-435. DOI: 10.31925/farmacia.2020.3.7. **FI: 1.607**. Citări:4.
- [12] Romaniuc A, **Bălașa R**, Știrbu N, Maier S, Andone S, Bajko Z, Bărcuțean L, Voidăzan S, Moțățăianu A. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. *Behavioural Neurology*. 2020, Article ID 2594702, DOI: 10.1155/2020/2594702. **FI: 1.908**. Citări:0. [\[PubMed\]](#)
- [13] Moțățăianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. **FI: 2.883**. Citări:3. [\[PubMed\]](#)

- [14] Hutanu A, Iancu M, Maier S, **Balasa R**, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: A single center study. *Ann Ind Acad Neurol.* 2020;23:496-503. Doi:10.4103/aian.AIAN_74_19. **FI: 0.898.** Citări:2. [\[PubMed\]](#)
- [15] **Bălașa R**, Maier S, Bărcuțean L, Stoian A, Moțățianu A. The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: one possible link between neuroinflammation and neurodegeneration. *Revista Română de Medicină de Laborator* 2020, 28 (1), DOI:10.2478/rrlm-2020-0005. **FI: 0.800.** Citări:3.
- [16] Maier S, Moțățianu A, Bărcuțean L, Balint A, Huțanu A, Bajko Z, Stoian A, Romaniuc A, Andone S, **Bălașa R**. Interferon- β 1a, an immunomodulator in relapsing remitting multiple sclerosis patients. The effect on pro-inflammatory cytokines. *Farmacia* 2020, 68 (1). DOI:10.31925/farmacia.2020.1.10, **FI: 1.527.** Citări:3.
- [17] Karelis G, **Balasa R**, De Bleecker J, Stuchevskaya T, Villa An, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayaguasanosa J. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. *Eur Neurol.* 2019;81(:223-230. **FI: 1.23.** Citări:8. [\[PubMed\]](#)
- [18] Hutanu A, Iancu M, Dobreanu M, Oprea OR, Barbu S, Maier S, Tero-Vescan A, Bajko Z, **Balasa R**. Extended lipid profile in Romanian ischemic stroke patients in relation to stroke severity and outcome:a path analysis model. *Arch Med Sci* 2019; <https://doi.org/10.5114/aoms.2019.89302>. **FI: 2.280.** Citări:1.
- [19] Bajko Z, Filep RC, Maier S, Motataianu A, Andone S, **Balasa R**. Bilateral vertebral artery without stroke secondary to giant cell arteritis. *Acta Reumatol Port* 2019; 44:155-157. **FI: 0.776.** Citări:1. [\[PubMed\]](#)
- [20] Maier S, Copotoiu M, Romaniuc A, Andone S, **Bălașa R**. Central-variant reversible encephalopathy syndrome in a young patient with systemic lupus erythematosus. *Acta Neurol Belgica* 2019; 119: 269-271. **FI: 1.612.** Citări: 1. [\[PubMed\]](#)
- [21] Bărcuțean LI, Romaniuc A, Maier S, Bajkó Z, Moțățianu A, Huțanu A, Simu I, Andone S, **Bălașa R**. Clinical and serological biomarkers of treatment's response in patients treated continuously with interferon β -1b for more than a decade. *CNS Neurol Disord Drug-Targets* 2018; 17: 720-792. **FI: 2.084.** Citări:8. [\[PubMed\]](#)
- [22] Bajkó Z, Andone S, Buruiian M, Filep R, **Bălașa R**. Unilateral deep cerebral venous sinus thrombosis with reversible secondary parkinsonism. *Acta Neurol Belgica.* Epub 2018. 2020;120:503-506. DOI: 10.1007/s13760-018-0982-0. **FI: 1.612.** Citări:2. [\[PubMed\]](#)
- [23] Moțățianu A, Maier S, Bajkó Z, Voidazan S, **Bălașa R**, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. *BMC Neurology* 2018; 18: 126. Doi: 10.1186/s12883-018-1125-1. **FI: 2.48.** Citări:14. [\[PubMed\]](#)
- [24] **Bălașa R**, Ciorba B, Voidazan S, Simu I, Huțanu A, Andone S, Romaniuc A, Moțățianu A, Maier S. The matrix metalloproteinases panel in multiple sclerosis patients treated with Natalizumab: A possible answer to Natalizumab non-responders. *CNS Neurol Disord Drug-Targets* 2018; 17: 464-472. **FI: 2.084.** Citări:5. [\[PubMed\]](#)
- [25] Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. **FI: 0.99.** Citări:16. [\[PubMed\]](#)
- [26] Huțanu A, Maier M, **Bălașa R**, Oprea OR, Barbu Ș, Voidăzan S, Dobreanu M. Plasma phosphorylated neurofilament heavy chains as a potential marker for ischemic stroke

- patients. Rom J Lab Med 2018; 26: 59-64. DOI: <https://doi.org/10.2478/rrlm-2018-0004>. **FI: 0.325**. Citări:1.
- [27] **Bălașa R**, Simu M, Voidăzan S, Bărcuțean LI, Bajko Z, Huțanu A, Simu I, Maier S. Natalizumab changes the peripheral profile of the Th17 panel in MS patients: New mechanisms of action. CNS Neurol Disord Drug-Targets 2017; 16: ISSN: 1018-1026. **FI: 2.188**. Citări:16. [\[PubMed\]](#)
- [28] Maier S, **Bălașa R**, Bajkó Z, Simu I, Horvath E. Complete progressive ophthalmoplegia and numb chin syndrome, the first clinical manifestations of a lethal abdominal Burkitt lymphoma. Neurol Neurochir Polska 2017; 51: 510-513. **FI: 0.857**. Citări:1. [\[PubMed\]](#)
- [29] **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățaiianu A, Țilea B, Tiu C. Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta 1 serum titers in relapsing remitting multiple sclerosis patients treated with Avonex, possible biomarkers for treatment response. CNS Neurol Disord Drug- Targets 2017; 16: 93-101. **FI: 2.188**. Citări:11. [\[PubMed\]](#)
- [30] Țilea B, Voidăzan S, **Bălașa R**, Huțanu A, Fodor A. CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of central nervous system. Rom J Lab Med 2017; 25: DOI:10.1515/rrlm-2016-0043. **FI: 0.325**. Citări:1.
- [31] Mărginean A, Bălănescu C, Moldovan V, Scridon A, Mărginean M, **Bălașa R**, Maier S, Țăruși M, Dobreanu M. The impact of CY2C19 polymorphism, clinical and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry. Clin Appl Thromb/Hemost 2017; 23: 255-265. **FI: 2.392**. Citări:13. [\[PubMed\]](#)
- [32] Maier S, Bajkó Z, Moțățaiianu A, Rusu S, **Bălașa R**. Giant internal carotid artery aneurysm causing Collet-Sicard syndrome. Acta Neurol Belgica 2017; 117: 295-297. **FI: 0.894**. Citări:2. [\[PubMed\]](#)
- [33] Bălașa A **Bălașa R**, Egyed-Zsigmond I, Chinezu R. Bilateral thalamic glioma: case report and review of the literature. Turk Neurosurg 2016; 26: 321-324. **FI: 0.576**. Citări:5. [\[PubMed\]](#)
- [34] **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățaiianu A. An intricate mechanism of action of Avonex in relapsing remitting multiple sclerosis patients: variation of serum titre of interleukin-17A, interleukin-10 and transforming growth factor-beta. CNS Neurol Disord Drug Targets 2015; 14: 804-810. **FI: 2.702**. Citări:7. [\[PubMed\]](#)
- [35] **Bălașa R**, Maier S, Bajkó Z, Pașcanu I, Moțățaiianu A. Skeletal muscle Na⁺/K⁺-ATPase pump dysfunction in thyrotoxic periodic paralysis: case report. Acta Endocrinol (Buc) 2015; 11: 240-245. **FI: 0.210**. Citări:2.
- [36] **Bălașa R**, Maier S, Bajkó Z, Moțățaiianu A, Crișan A, Bălașa A. Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. Acta Neurol Belgica 2015; 115: 635-642. **FI: 0.598**. Citări:4. [\[PubMed\]](#)
- [37] Maier S, Buruiian M, Maier A, Moțățaiianu A, Voidăzan S, Bajkó Z, **Bălașa R**. The determinants of depression in a Romanian cohort of multiple sclerosis patients. Acta Neurol Belgica 2015; DOI: 10.1007/s13760-015-0547-4. **FI: 0.598**. Citări:4 [\[PubMed\]](#)
- [38] Bajkó Z, **Bălașa R**, Szatmári S, Rusu S, Moțățaiianu A, Maier S. The role of ultrasound in the diagnosis of temporal arteritis. Neurol Neurochir Polska 2015; 49: 139-143. **FI: 0.641**. Citări:3. [\[PubMed\]](#)
- [39] Stoian A, Bănescu C, **Bălașa R**, Moțățaiianu A, Stoian M, Moldovan VG, Voidăzan S, Dobreanu M. Influence of GSTM1, and GSTP1 polymorphisms on type 2 diabetes

- mellitus and diabetic sensorimotor peripheral neuropathy risk. *Dis Markers* 2015; ID 638693. **FI: 1.562**. Citări:23. [\[PubMed\]](#)
- [40] Jung I, Gurzu S, **Bălașa R**, Moțățăianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. **FI: 4.256**. Citări:12. [\[PubMed\]](#)
- [41] **Bălașa R**, Maier S, Gliga Baubec E, Bajkó Z, Bălașa A. Cerebellar and brainstem variant of posterior reversible encephalopathy syndrome. *Acta Neurol Belg* 2015; 115: 401-403. **FI: 0.598**. Citări:1. [\[PubMed\]](#)
- [42] **Bălașa R**, Bajkó Z, Moțățăianu A, Maier A, Maier S. Neuromyelitis optica associated with painful dystonia: case report and literature review. *Acta Neurol Belg* 2015; 115: 169-171. **FI: 0.598**. Citări:1. [\[PubMed\]](#)
- [43] **Bălașa R**, Maier S, Moțățăianu A, Bajkó Z, Moldovan O, Benedek E. A case of fatal acute intermittent porphyria: laboratory diagnosis and pathogenesis considerations. *Rev Rom Med Lab* 2014; 22: 325-333. **FI: 0.171**. Citări:1.
- [44] Treabă AC, **Bălașa R**, Podoleanu DM, Simu IP, Buruian MM. Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? *Diagn Interv Radiol* 2014; 20: 178-184. **FI: 1.427**. Citări:9. [\[PubMed\]](#)
- [45] Moțățăianu A, **Bălașa R**, Voidăzan S, Bajkó Z. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. *BioMed Res Internat* 2013, Article ID 507216. **FI: 2.706**. Citări:11. [\[PubMed\]](#)
- [46] **Bălașa R**, Bajkó Z, Huțanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. *Mult Scler J* 2013; 19: 885-890. **FI: 4.863**. Citări:27. [\[PubMed\]](#)
- [47] **Bălașa R**, Huțanu A, Bajkó Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-beta treatment in multiple sclerosis? *Rom J Lab Med* 2011; 19: 381-389. **FI: 0.091**. Citări:10.
- [48] **Bălașa R**, Huțanu A, Feier C, Bajkó Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon- β treatment in multiple sclerosis patients. *Rom J Lab Med* 2010; 18: 39-50. **FI: 0.113**. Citări:2.

V. Lucrări științifice de specialitate publicate în extenso în reviste cotate ISI cu FI, articole colective

- [1] Kappos L, Bar-Or A, Bruce ACL, Fox RJ, Giovannoni G, Gold R, Vermersch P, Douglas LA, Arnould S, Scherz T, Wolf C, Wallstrom E, Dahlke F, Expand Clinical investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018;391:1263-1273.. Citări: 271. **FI: 59.102** [\[PubMed\]](#)
- [2] Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, Ecans SR, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, SOCRATES Steering Committee and Investigators. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). *Circulation*. 2017;136:907-916. Citări:14. **FI: 15.211**. [\[PubMed\]](#)
- [3] Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CAM, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Vignietta V, Dawson KT, CONFIRM study investigators. Effects of delayed-release

- dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. 2015;84:1145-1152. Citări:**39. FI: 8.286.** [\[PubMed\]](#)
- [4] Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffrey D, Kappos L, Montalban X, Boyko AN, Comi G, Allegro Study group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. *J Neurol Neurosurg Psychiatry*. 2014;85:851-858. Citări:**78. FI: 7.38.** [\[PubMed\]](#)
- [5] Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. *Lancet Neurol* 2014; 13: 657-665. Citări: **219. IF: 21.823.** [\[PubMed\]](#)
- [6] Leist TP, Comi G, Cree BAC, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with first demyelinating event (ORACLE MS): a phase 3 randomised trial. *Lancet Neurol* 2014; 13: 257-267. Citări: **109. IF: 21.823.** [\[PubMed\]](#)
- [7] Comi G, Martinelli V, Rodegher M, et al. Effect of early treatment with glatiramer acetate in patients with clinically isolated syndrome. *Mult Scler J* 2013; 19: 1074-1083. Citări: **59. IF: 4.863.** [\[PubMed\]](#)
- [8] Fox JR, Miller DH, Phillips T, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med* 2012; 367: 1087-1097. Citări: **4. IF: 51.658.** [\[PubMed\]](#)
- [9] Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral Laquinimod for multiple sclerosis. *N Engl J Med* 2012; 366: 1000-1009. Citări: **268. IF: 51.658.** [\[PubMed\]](#)
- [10] Radue E-W, O'Connor, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. *Arch Neurol* 2012; 69: 1259-1269. Citări: **78. IF: 7.580.** [\[PubMed\]](#)
- [11] Baulac, Brodie M, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. *Lancet Neurol* 2012; 11:579-588. Citări: **93. IF: 23.917.**
- [12] Kappos L, Radue E-W, O'Connor, et al. A placebo-controlled trial of oral Fingolimod in relapsing multiple sclerosis. *N Engl J Med* 2010; 362: 387-401. Citări: **1706. IF: 53.484.** [\[PubMed\]](#)
- [13] Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet* 2009; 374:1503-1511 Citări: **386. IF: 30,758.** [\[PubMed\]](#)
- [14] De Stefano N, Filippi M, Hawkins C, et al. Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis. *J Neurol Sci* 2008; 266: 44-50. Citări: **10. IF: 2,359.** [\[PubMed\]](#)
- [15] Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of DNA vaccine encoding myelin basic protein for multiple sclerosis. *Ann Neurol* 2008; 63: 611-620. Citări: **130. IF: 9.935.** [\[PubMed\]](#)

VI. Lucrări științifice de specialitate publicate în extenso în reviste cotate CNCSIS B+ / ISI fara FI.

- [1] Draghici I, Marginean L, Filep RC, Bajko Z, Barcutean L, Aldea T, **Balasa R.** Postpartum Acute Basilar Artery Occlusion Secondary to Vertebral Artery Dissection. Case Report and Literature Review. *J Crit Care Med.* 2021; ahead of print. DOI: 10.2478/jccm-2021-0015.
- [2] Mosora O, Barcutean L, **Balasa R,** Fodor R, Maier S, Bajko Z, Stoian A, Motataianu A. Severe Acute Motor Axonal Neuropathy Associated with Influenza-A (H1N1) Infection and Prolonged Respiratory Failure – A Case Report. *J Crit Care Med.* 2021; ahead of print. DOI: 10.2478/jccm-2021-0030.
- [3] Andone S, **Balasa R,** Barcutean L, Bajko Z, Motataianu A, Stoian A, Maier S. Contrast Medium-Induced Encephalopathy after Coronary Angiography – Case Report. *J Crit Care Med.* 2021;7:145-149.
- [4] **Balasa R.** Therapeutic Plasma Exchange: An Indispensable Therapy for Severe Neurological Condition. *J Crit Care Med.* 2020;6:89-90.
- [5] Serban G, **Balasa R.** SARS-CoV2 infection in a multiple sclerosis patient treated with natalizumab - A case presentation. *Acta Medica Marisiensis.* 2020;66:110-112.
- [6] Serban G, Balasa R. Review on multiple sclerosis management in times of SARS-CoV-2 pandemic. *Romanian Journal of Neurology.* 2020;19:70-75.
- [7] Bărcuțean LB, Maier S, Bajko Z, Moțățaiianu A, Romaniuc A, Andone SR, **Bălașa R.** Interferon beta-1b for the treatment of multiple sclerosis – more than 10 years of experience. *Acta Medica Marisiensis* 2019; 65: 12-18.
- [8] Moțățaiianu A, Maier S, Gothard A, Bajko Z, **Bălașa R.** Severe fatal systemic embolism due to non-bacterial thrombotic endocarditis as the initial manifestation of gastric adenocarcinoma: Case report. *J Crit Care Med* 2018; 4: 68-73.
- [9] Bajko Z, Andone S, Maier S, Moțățaiianu A, Copotoiu M, Romaniuc A, Barcutean L, Stoian A, **Bălașa R.** Infarction of the posterior limb of internal capsule: The first clinical manifestation of lupus. *Rom J Neurol* 2018; 17: 168-171.
- [10] Bajkó Z, Maier Z, Moțățaiianu A, **Bălașa R,** Vasiiu S, Stoian S. Stroke secondary to traumatic carotid artery injury. A case report. *J Crit Care Med* 2018; 4: 23-28.
- [11] Andone S, Petruțiu S, Bajkó Z, Moțățaiianu A, Maier S, Macavei I, Stoian A, Bălașa A, **Bălașa R.** Sporadic Creutzfeldt-Jakob disease: a clinical approach of a small case series and literature review. *Rom J Neurol* 2017; 16: 109-115.
- [12] Gál R, **Bălașa R,** Bajkó Z, Maier S, Simu I, Bălașa A. Lethal subarachnoid and intracerebral haemorrhage associated with temporal arteritis. A case report. *J Crit Care Med* 2017; 3: 153-157.
- [13] Gál R, **Bălașa R,** Bajkó Z, Maier S, Simu I, Bălașa A. Lethal subarachnoid and intracerebral haemorrhage associated with temporal arteritis. A care report. *J Crit Care Med* 2017 3: 153-157.
- [14] Maier S, Bajkó Z, Moțățaiianu A, Stoian A, Șchiopu B, **Bălașa R.** Late Onset Tay-Sachs Disease in a Non-Jewish Patient: Case Report. *Acta Marisiensis-Seria Medica* 2017;63(4):199-203.
- [15] Stoian A, **Bălașa R,** Bărcuțean L, Moțățaiianu A, Mocanu S. An unusual cause of longitudinally extensive transverse myelitis - case report. *Human & Veterinary Medicine* 2017;9:161-165.
- [16] **Bălașa R.** The eleventh hour: Neurosyphilis, still fashionable but a controversial diagnosis. *J Crit Care Med* 2017: 3; 53-55.

- [17] Maier S, Stirbu N, Bajkó Z, Moțățăianu A, Țilea B, Alexandrescu A, **Bălașa R**. Lyme meningoradiculitis: case reports and literature review. *Acta Medica Marisiensis* 2016; 62: 373-375.
- [18] Bajkó Z, **Bălașa R**, Moțățăianu A, Bărcuțean L, Stoian A, Stirbu N, Maier S. Malignant middle cerebral artery infarction secondary to traumatic bilateral internal carotid artery dissection. A case report. *J Crit Care Med* 2016; 2: 135-141.
- [19] Moțățăianu A, Bajkó Z, Maier S, Stoian A, Bărcuțean L, **Bălașa R**. Correlations between the severity of cardiovascular autonomic neuropathy and other complications in type 2 diabetes mellitus. *Rom J Neurol* 2016; 15: 16-23.
- [20] Bajkó Z, Maier S, Moțățăianu A, Stoian A, Bărcuțean L, **Bălașa R**. Repetitive transient ischaemic attacks secondary to a floating carotid artery thrombus in a young patient with essential thrombocythemia. *J Cardiovasc Emerg* 2016; 2: 188-191.
- [21] Țilea B, **Bălașa R**, Fodor A, Țilea I. Diagnosis and treatment algorithm in Lyme neuroborreliosis. *Acta Medica Marisiensis* 2016; 62: 121-127.
- [22] Bajkó Z, **Bălașa R**, Moțățăianu A, Bărcuțean L, Stoian A, Stirbu N, Maier S. Malignant middle cerebral artery infarction secondary to traumatic bilateral internal carotid artery dissection. A case report. *The Journal of Critical Care Medicine* 2016; 2: 135-141.
- [23] Stoian A, Moțățăianu A, Bajkó Z, Maier Z, Bărcuțean L, Stoian M, **Bălașa R**. Cardiovascular and renal prognosis in patients with arterial hypertension, type 2 diabetes mellitus and microalbuminuria. *HVM Bioflux* 2016; 8: 45-49.
- [24] **Bălașa R**. Nanoneurology. *Rom J Neurol* 2015; 14: 189-204.
- [25] Molnar K, **Bălașa R**. Effect of serum 25(OH) D level, cigarette smoking and oral contraceptive use on clinical course of relapsing-remitting multiple sclerosis in a group of female patients. *Rom J Neurol* 2015; 14: 214-218.
- [26] **Bălașa R**, Bajkó Z, Maier S, Voidăzan S, Moțățăianu A. Influence of risk factors and diabetic complications on peripheral nerve function in type 2 diabetes mellitus. *Acta Medica Marisiensis* 2015; 61: 25-31.
- [27] Maier S, **Bălașa R**, Bajkó Z, Maier A, Șchiopu B, Buruian M. Correlation between depression, cognitive status, functional scores, disability and lesion load in multiple sclerosis treated with interferon beta 1a. *Acta Medica Marisiensis* 2015; 61: 32-37.
- [28] Maier S, **Bălașa R**, Buruian M, Maier A, Bajkó Z. Depression in multiple sclerosis. *Rom J Neurol* 2015; 14: 22-29.
- [29] **Bălașa R**, Doboczi M, Costache O, Maier S, Bajkó Z, Moțățăianu A, Bălașa A. Risk factors and diagnosis of cerebral venous thrombosis: data from a cohort of 45 Romanian patients. *Acta Medica Marisiensis* 2014; 60: 207-214.
- [30] **Bălașa R**, Bajkó Z, Maier Z, Moțățăianu A. The dual role of transforming growth factor beta in the pathogenesis of multiple sclerosis and experimental encephalomyelitis. *Rom J Neurol* 2014; 13: 103-107.
- [31] **Bălașa R**, Huțanu A, Maier S. Serum interleukin-10 levels in multiple sclerosis patients treated with IFN- β 1A. *Acta Medica Transilvanica* 2014; 2: 193-196.
- [32] Băjenaru O, Antochi F, **Bălașa R**, Buraga I, Patrichi S, Simu M, Szatmári S, Tiu C, Zaharia C, et VTE-NEURO study group. Assessment of venous thrombolism prophylaxis in neurological patients with restricted mobility – VTE-NEURO study. *Mædica J Clin Med (Buc)* 2014; 9: 6-14.
- [33] **Bălașa R**, Bajkó Z, Moțățăianu A, Maier S. Pitfalls in the diagnosis of neurosyphilis – case report and literature review. *Acta Medica Transilvanica* 2014; 2: 201-203.
- [34] Maier S, Bajkó Z, Moțățăianu A, Maier A, Raicea V, Bardas A, **Bălașa R**. Subclavian double steal syndrome presenting with cognitive impairment and dizziness. *Rom J Neurol* 2014; 13: 144-149.

- [35] **Bălașa R**, Bajkó Z, Bălașa A, Mocan S, Chebuț O. An unusual case of seronegative Wegener's granulomatosis: acute pancreatitis at onset, followed by atrio-ventricular block, neurological and kidney involvement. *Rom J Neurol* 2013; 12: 43-46.
- [36] Bajkó Z, **Bălașa R**, Maier S, Moțățăianu A, Treabă A, Macarie I, Gârbovan C, Chiriac C. *Listeria Monocytogenes* meningoencephalitis mimicking stroke in a patient with chronic lymphocytic leukemia. *Neurol & Ther* 2013; 2: 63-70.
- [37] Bajkó Z, **Bălașa R**, Moțățăianu A, Maier S, Chebuț OC, Szatmári S. Common carotid artery occlusion: a case series. *ISRN Neurol* 2013, Article ID 198595.
- [38] Moțățăianu A, Bajkó Z, Stoian A, **Bălașa R**. Cardiovascular autonomic neuropathy and sensorimotor polyneuropathy in type 2 diabetes mellitus. *Acta Medica Marisiensis* 2012; 58: 243-247.
- [39] **Bălașa R**, Bajkó Z, Stan C. Extracranial jugular venous insufficiency in multiple sclerosis patients treated with interferon beta. *Acta Medica Marisiensis* 2011; 57: 566-570.
- [40] Bajkó Z, **Bălașa R**, Stan C, Moțățăianu A. Dissection of the cervicocerebral arteries – ultrasonic characteristics. *Acta Medica Marisiensis* 2011; 57: 413-417.
- [41] **Bălașa R**, Bajkó Z. Trigeminal neuralgia in multiple sclerosis: a clinical comparison of trigeminal neuralgia in patients with and without underlying multiple sclerosis. *Rom J Neurol* 2010; 9: 68-73.
- [42] Bajkó Z, **Bălașa R**, Petruțiu S, Toma L, Russu S, Pascu I. Mobile carotid artery thrombus. *Rom J Neurol* 2009; 8: 184-186.
- [43] Ștefanache F, **Bălașa R**, Boieru G, Cârciumaru N, Dutoiu H, Georgescu C, Mărginean I, Perju-Dumbravă L, Zaharia C. Monitorizarea eficacității și siguranței Bilobil Forte la pacienții cu disfuncții cognitive severe. *Rom J Neurol* 2008; 7: 88-89.
- [44] **Bălașa R**, Mihaș E, Lukacs E. Tulburările cognitive în scleroza multiplă. *Rev Med Farm* 2008; 54: 136-145.
- [45] **Bălașa R**. Pediatric multiple sclerosis. *Rom J Neurol* 2007; 6: 171-175.

VII. Lucrări științifice de specialitate publicate în extenso în reviste cotate B/C

- [1] **Bălașa R**, Feier C, Dan M, Moțățăianu A, Balaianu M, Chebuț C, Constantin V, Bajkó Z, Pascu I. The prevalence of multiple sclerosis in Mures County, Central Romania. *Rev Rom Neurol* 2007; 6: 80-84.
- [2] **Bălașa R**. Hipotermia controlată în atacul cerebrovascular. *Rev Rom Neurol* 2007; 6: 3-8.
- [3] **Bălașa R**. Scleroza multiplă primar progresivă. *Rev Rom Neurol* 2006; 5: 135-141.
- [4] Pascu I, **Bălașa R**. Moartea creierului. *Brit Med J-Ed Română* 2004; 11: 90-95.
- [5] Pascu I, **Bălașa R**. Principii de tratament ale epilepsiei la adult. *Rev Rom Neurol* 2003; 2: 6-8.
- [6] **Bălașa R**. Potențialele evocate în scleroza multiplă și nevrita optică. *Rev Med Farm* 2001; 47: 131-136.
- [7] **Bălașa R**. Nevrita optică și relația acesteia cu scleroza multiplă. *Rev Med Farm* 2001; 47: 1-7.
- [8] Corfariu O, Chioreanu M, **Bălașa R**, Dicui S. Explorări de electroneurofiziologie clinică la bolnavul critic în unitățile de terapie intensivă. *J Soc Rom ATI* 2001; 8: 134-137.
- [9] **Bălașa R**. Visual evoked potentials and magnetic resonance imaging in multiple sclerosis patients with clinical and subclinical optic neuritis. *Rev Med Farm* 2000; 46: 245-247.
- [10] **Bălașa R**. Imagistica prin rezonanță magnetică în scleroza multiplă și nevrita optică. *Rev Med Farm* 2000; 46: 9-20.
- [11] Moldovan E, **Bălașa R**. Modificări microscopice în timus la bolnavii cu myasthenia gravis. *Rev Med Farm* 1999; 45: 218-222.
- [12] Pascu I, Pascu R, **Bălașa R**. Borrelioza (boala Lyme). *Rev Med Farm* 1998; 44: 252-260.